Apr 14, 2021 6:00am EDT Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
Apr 12, 2021 5:52am EDT REPEAT/Greenwich LifeSciences Presents Phase IIb Poster, Published April 10th at 2021 AACR Annual Meeting, Showing GP2 Immune Response Peaked at 6 Months, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Apr 10, 2021 4:13pm EDT Greenwich LifeSciences Presents Immune Response Phase IIb Poster, Published Today at AACR 2021, Showing Peak Immunity after 6 Months of GP2 Treatment, Resulting in 100% Disease Free Survival from Recurring Breast Cancer
Apr 09, 2021 5:00am EDT Greenwich LifeSciences Reports Robust Immune Response Phase IIb Data Supporting GP2 Clinical Outcome of 0% Metastatic Breast Cancer Recurrences Over 5 Years of Follow-up
Mar 23, 2021 6:00am EDT Greenwich LifeSciences CEO to Participate on Cancer Panel and to Present at Benzinga Biotech Conference
Mar 11, 2021 6:00am EST Greenwich LifeSciences Updates 2021 Timeline & Announces Two Upcoming Presentations at the American Association for Cancer Research Annual Meeting
Mar 08, 2021 6:00am EST Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Mar 02, 2021 6:00am EST Greenwich LifeSciences to Present at Multiple Investor Conferences, Including H.C. Wainwright Global Life Sciences and BIO-Europe Spring Conferences
Feb 25, 2021 6:00am EST Greenwich LifeSciences Announces Acceptance of Two Abstracts at Upcoming Major Cancer Conference